Comprehensive analysis of Slc15a3 and Myo1f gene expression in renal carcinoma: Insights from RNA-seq data and validation via qRT-PCR

Early detection of renal cell carcinoma (RCC) remains a challenge. Identification of novel biomarkers may improve the diagnosis, prognosis, and treatment of RCC. This study aimed to identify potential novel biomarkers for RCC by analyzing gene expression profiles by RNA sequencing (RNA-seq) and validating the results by laboratory tests. Data were retrieved from NCBI GEO datasets. After data processing and analysis, two genes with differential expression in RCC were selected: Slc15a3 and Myo1f. Blood samples were then collected from 26 RCC patients and 24 healthy controls. Following the extraction of RNA and the synthesis of cDNA, real-time polymerase chain reaction (PCR) was conducted. The expression of genes was evaluated and analyzed using GraphPad Prism, with a statistical significance threshold of P < 0.05. In silico analysis and RNA-seq data revealed that Slc15a3 and Myo1f were differentially expressed in RCC. Real-time PCR results showed a significant increase in Myo1f expression in RCC patients ( P < 0.05), suggesting its potential as a novel biomarker. However, Slc15a3 did not show significant expression differences between RCC patients and controls ( P > 0.05), indicating a limited biomarker potential. This study suggests that Myo1f maybe a promising biomarker for RCC.